Prediction of postembolization syndrome after transarterial chemoembolization of hepatocellular carcinoma and its impact on prognosis
Authors:
- Natascha RoehlenNRNatascha Roehlen
- Fabian StoehrFSFabian Stoehr
- Lukas MüllerLMLukas Müller
- Hendrik LuxenburgerHLHendrik Luxenburger
- Simon J. GairingSGSimon J. Gairing
- Marlene ReinckeMRMarlene Reincke
- Michael SchultheissMSMichael Schultheiss
- Arndt WeinmannAWArndt Weinmann
- Friedrich FoersterFFFriedrich Foerster
- Jens U. MarquardtJens U. Marquardt
- Robert ThimmeRTRobert Thimme
Open Access
- 27 September 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (10)
Abstract
Background: Postembolization syndrome (PES) represents the most frequent complication after transarterial chemoembolization (TACE) in patients with HCC. Given the vague definition as a symptom complex comprising abdominal pain, fever, and nausea, PES is diagnosed in heterogeneous patient cohorts with symptoms ranging from mild pain to severe deterioration of their general condition. This study aimed to evaluate predictive factors and the prognostic impact of PES with regard to different severity grades. Methods: A total of 954 patients treated with TACE for HCC at the University Medical Centres Mainz and Freiburg were included in this study. PES disease severity was graded as mild, moderate, or severe according to a predefined combination of symptoms. Logistic regression models were used to identify independent predictors of PES. The prognostic impact of PES was evaluated by competing risk analyses considering liver transplantation as a competing risk. Results: PES occurred in 616 patients (64.5%), but only 56 patients (5.9%) had severe PES, defined as moderate to severe abdominal pain requiring opioids in combination with fever and nausea. The largest tumor diameter was the strongest independent predictor of PES (OR = 1.21, 95% CI = 1.13–1.28), and severe PES (OR = 1.23, 95% CI = 1.14–1.33, p < 0.0001). Presence of liver cirrhosis was protective against PES (OR = 0.48, 95% CI = 0.27–0.84, p = 0.01). Furthermore, PES was independently associated with an impaired disease control rate (OR = 0.33, 95% CI = 0.16–0.69, p = 0.003) and severe PES with poor overall survival (subdistribution HR = 1.53, 95% CI = 0.99–2.36, p = 0.04). Conclusions: Tumor size and absence of liver cirrhosis are predictors of severe PES and associated with impaired prognosis in HCC patients after TACE.Keywords
This publication has 33 references indexed in Scilit:
- Management of Postembolization Syndrome Following Hepatic Transarterial Chemoembolization for Primary or Metastatic Liver CancerCancer Nursing, 2016
- Post‐embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinomaHPB, 2015
- Transarterial chemoembolization: Modalities, indication, and patient selectionJournal of Hepatology, 2015
- Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinomaJournal of Hepatology, 2012
- Safety and Feasibility of Same-day Discharge of Patients with Unresectable Hepatocellular Carcinoma Treated with Doxorubicin Drug-eluting Bead Transcatheter ChemoembolizationJournal of Vascular and Interventional Radiology, 2012
- Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial designJournal of Hepatology, 2012
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V StudyCardioVascular and Interventional Radiology, 2009
- A New Way: Alleviating Postembolization Syndrome Following Transcatheter Arterial ChemoembolizationThe Journal of Alternative and Complementary Medicine, 2009
- Does Postembolization Fever after Chemoembolization Have Prognostic Significance for Survival in Patients with Unresectable Hepatocellular Carcinoma?Journal of Vascular and Interventional Radiology, 2009
- Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokineticsJournal of Hepatology, 2007